These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 6203542)

  • 1. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
    Garrick NA; Scheinin M; Chang WH; Linnoila M; Murphy DL
    Biochem Pharmacol; 1984 May; 33(9):1423-7. PubMed ID: 6203542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
    Garrick NA; Seppala T; Linnoila M; Murphy DL
    Eur J Pharmacol; 1985 Mar; 110(1):1-9. PubMed ID: 2408906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
    Potter WZ; Scheinin M; Golden RN; Rudorfer MV; Cowdry RW; Calil HM; Ross RJ; Linnoila M
    Arch Gen Psychiatry; 1985 Dec; 42(12):1171-7. PubMed ID: 2416297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minipump clorgyline administration and CSF amine metabolites in unrestrained monkeys.
    Cox M; Garrick N; Reite M; Gennaro M
    Pharmacol Biochem Behav; 1991 Mar; 38(3):677-9. PubMed ID: 1712497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.
    Garrick NA; Seppala T; Linnoila M; Murphy DL
    Psychopharmacology (Berl); 1985; 86(3):265-9. PubMed ID: 2412251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
    Waldmeier PC; Baumann PA
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
    Sunderland T; Tariot PN; Cohen RM; Newhouse PA; Mellow AM; Mueller EA; Murphy DL
    Psychopharmacology (Berl); 1987; 91(3):293-6. PubMed ID: 2436247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
    Braestrup C; Andersen H; Randrup A
    Eur J Pharmacol; 1975 Nov; 34(1):181-7. PubMed ID: 1241962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary prolactin as a marker for central serotonin turnover.
    Lindell SG; Suomi SJ; Shoaf S; Linnoila M; Higley JD
    Biol Psychiatry; 1999 Aug; 46(4):568-72. PubMed ID: 10459408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC; Delini-Stula A; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical effects of antidepressant treatment--studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding.
    Asberg M; Wägner A
    Ciba Found Symp; 1986; 123():57-83. PubMed ID: 2434288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
    Murphy DL; Lipper S; Slater S; Shiling D
    Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
    Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG
    Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y; Bardgett ME; Csernansky JG
    J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between platelet MAO activity and concentrations of 5-HIAA and HVA in cerebrospinal fluid in chronic pain patients.
    von Knorring L; Oreland L; Häggendal J; Magnusson T; Almay B; Johansson F
    J Neural Transm; 1986; 66(1):37-46. PubMed ID: 2426397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine metabolites in ventricular CSF of children with posterior fossa tumors: correlation with tumor histology and cognitive functioning.
    Varela M; Alexiou GA; Liakopoulou M; Papakonstantinou E; Pitsouni D; Alevizopoulos GA
    J Neurosurg Pediatr; 2014 Apr; 13(4):375-9. PubMed ID: 24559277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state.
    Fujimoto A; Nagao T; Ebara T; Sato M; Otsuki S
    Biol Psychiatry; 1983 Oct; 18(10):1141-52. PubMed ID: 6197099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive mortality in young free-ranging male nonhuman primates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations.
    Higley JD; Mehlman PT; Higley SB; Fernald B; Vickers J; Lindell SG; Taub DM; Suomi SJ; Linnoila M
    Arch Gen Psychiatry; 1996 Jun; 53(6):537-43. PubMed ID: 8639037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid monoaminergic metabolites differ in wild anubis and hybrid (Anubis hamadryas) baboons: possible relationships to life history and behavior.
    Kaplan JR; Phillips-Conroy J; Fontenot MB; Jolly CJ; Fairbanks LA; Mann JJ
    Neuropsychopharmacology; 1999 Jun; 20(6):517-24. PubMed ID: 10327421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.